Quince Therapeutics (NASDAQ:QNCX – Get Free Report) and Humacyte (NASDAQ:HUMA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
Valuation & Earnings
This table compares Quince Therapeutics and Humacyte’s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Quince Therapeutics | N/A | N/A | -$31.39 million | ($0.84) | -1.18 |
Humacyte | $1.57 million | 333.74 | -$110.78 million | ($1.07) | -4.11 |
Quince Therapeutics has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Quince Therapeutics | 0 | 0 | 0 | 0 | N/A |
Humacyte | 0 | 1 | 3 | 0 | 2.75 |
Humacyte has a consensus price target of $8.00, indicating a potential upside of 81.82%. Given Humacyte’s higher possible upside, analysts clearly believe Humacyte is more favorable than Quince Therapeutics.
Volatility & Risk
Quince Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Institutional & Insider Ownership
30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 27.9% of Quince Therapeutics shares are held by insiders. Comparatively, 23.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Quince Therapeutics and Humacyte’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Quince Therapeutics | N/A | -36.36% | -28.83% |
Humacyte | N/A | -199.62% | -61.45% |
Summary
Quince Therapeutics beats Humacyte on 6 of the 11 factors compared between the two stocks.
About Quince Therapeutics
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.